Learn the latest from AAP and CDC experts as they discuss how pediatric clinicians can prepare their practices for the 2024-2025 respiratory virus season. This webinar was recorded on August 27, 2024.
-
(4:44) CDC Presentation
(6:09) Who should get 2024-2025 COVID-19, influenza, and RSV immunization?
(7:18) When should we be giving these immunizations?
(8:16) What steps can I take to prepare my clinic?
(9:31) What is the evidence to support these immunization recommendations?
(9:39) Why vaccinate kids against COVID-19?
(11:21) Why vaccinate kids against influenza?
(12:30) Why immunize against RSV?
(13:27) How should I counsel patients about nirsevimab and maternal RSV vaccine?
(15:48) What are available treatments for COVID-19 and influenza?
(16:44) What is the anticipated supply of maternal RSV vaccine and nirsevimab for the 2024-2025 season?
(17:36) What is CDC doing to protect AI/AN infants and children?
(18:30) What can I do to increase vaccine coverage in my clinic?
(19:13) What is the best way to talk to parents about vaccines?
(20:09) Does health insurance cover immunizations?
(20:36) How do I report adverse events following nirsevimab administration?
(21:00) Update on recent Health Advisory about Human Parvovirus B19 activity increase.
(21:40) Healthcare Provider Call to Action for Respiratory Virus Season
(22:44) Comments from Dr Sean O’Leary about AAP Recommendations
(25:30) Question and Answer Session
(25:40) Why are we continuing to recommend COVID-19 vaccine?
(27:23) What is the recommendation for an infant less than 8 months of age who was born late in the season and received nirsevimab or whose gestational parent received RSV vaccine? If they are still under 8 months of age in October but do not have underlying health conditions, should they receive nirsevimab this season?
(28:36) Should an infant who did not receive a dose of nirsevimab last year due to supply issues receive a dose this season if they’re over 8 months of age?
(29:35) AI/AN patients have been identified as a high-risk group for nirsevimab in a child’s second season of life. What is CDC doing to help ensure that patients from AI/AN backgrounds, as well as those in rural and under resourced areas, are better protected from RSV?
(31:50) What is CDC doing to facilitate VFC enrollment for birthing hospitals?
(34:06) Does CDC have any recommendations on verification of maternal RSV vaccine (Abrysvo) administration?
(37:52) What is the potential risk of pre-term birth with maternal RSV vaccine (Abrysvo)?
(39:32) If both nirsevimab and palivizumab are available for eligible high-risk patients, which should they receive?
(40:12) What strategies are being used to ensure equitable distribution of nirsevimab for families with commercial and publicly funded insurance?
(41:40) Do you anticipate that RSV epidemiology will look different after maternal vaccination and nirsevimab administration last season?
(42:44) For COVID and influenza, are there any best practices for people with disabilities, particularly in schools?
(45:09) Should I get the updated vaccine if I have COVID-19, or I recently had COVID-19? What should health care providers be communicating about COVID-19 vaccine safety to their patients?
(48:44) What are the current recommendations for return-to-work post-COVID infection for health care workers?
(49:31) Our office has discontinued testing for COVID-19 due to poor insurance payment. Can we rely on rapid home tests for diagnosis?
(51:24) We have had pregnant people receiving Abrysvo outside of the recommended Sept-Jan time frame. If Abrysvo was given earlier than September, should the infant receive nirsevimab?
-
Benjamin D. Hoffman, MD, FAAP (Moderator)
President, American Academy of PediatricsManisha Patel, MD, MS, MBA
Chief Medical Officer, National Center for Immunization and Respiratory Diseases (NCIRD), CDCKatherine Fleming-Dutra, MD, FAAP
Lead, Vaccine Effectiveness and Policy Team NCIRD, Coronavirus and Other Respiratory Viruses Division, CDCJennifer M. Nelson, MD, MPH, FAAP, DipABLM
Sr Advisor for Health Equity, Immunization Services Division, NCIRD, CDCCharlene Wong, MD, MSHP
Sr Advisor for Health Strategy, Immediate Office of the Director, CDCSean T. O’Leary, MD, MPH, FAAP
Chairperson, AAP Committee on Infectious Diseases
Last Updated
08/29/2024
Source
American Academy of Pediatrics